PharmaKodex
This article was originally published in The Tan Sheet
Executive Summary
A collaboration between Vectura and Unilever has resulted in the formation of the new PharmaKodex specialty pharmaceutical company, the firms announce May 15. The new entity will employ a range of proprietary oral, transdermal and enabling technologies from both companies to develop a pipeline of Rx and OTC products. Currently, the pipeline contains six nonprescription drugs in development. PharmaKodex plans to repurpose "existing drugs for new indications or combinations, or to provide an improved route of administration," according to the release. Vectura and Unilever both will "retain a significant shareholding in PharmaKodex," the firms state...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.